FDA
-
-
-
-
-
-
-
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
-
-
-
-
-
-
-
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Initiates Apraglutide NDA Submission
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Maintains FY 2023 Financial Guidance, Issues FY24 Guidance
-
-
-
-
-
-
-
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
-
335,195 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


